August 25th 2025
To the authors' knowledge, this is the first reported case of C pseudotuberculosis bloodstream infection in an infant.
Jason Roberts, PhD, notes that the BLING study has been a great success for infectious diseases and critical care as a research program, providing strong evidence supporting a meaningful intervention for patients, specifically in clinical cure rates and the occurrence of infections with multiresistant organisms.
Watch
Continuous β-Lactam Infusions Show Promise in the Battle Against Sepsis
June 24th 2024Jason Roberts, PhD, discusses insights from the BLING III trial, outlining its study design and primary outcomes. His analysis centers on the clinical benefits of continuous infusions while addressing the complexities of antibiotic administration in critical care. This is part 1 of a 2-part series.
Watch
Top Infectious Disease News Stories Week of June 1-7
June 7th 2024FDA VRBPAC recommends protection against JN1 for the fall COVID-19 vaccines, a multidrug-resistant form of gonorrhea gives cause for concern, piperacillin-tazobactam shown to have higher mortality than cefepime for sepsis, and more this week from Contagion.
Read More
750,000 Global Deaths Linked to AMR Could be Prevented Annually
May 28th 2024A new series reviewing antimicrobial resistance (AMR) reduction strategies shows that available vaccines, water and sanitation, and infection control methods could greatly reduce the mortality associated with this major health crisis.
Read More
Implementing Strategies and Measuring Interventions to Reduce Antimicrobial Stewardship Disparities
May 13th 2024In the second installment of the discussion around the Equity in Antimicrobial Stewardship Efforts (EASE), the codevelopers of this novel framework discuss how to move forward with interventions and measuring success around them.
Watch
A Novel Framework to Address Antimicrobial Stewardship Disparities
May 10th 2024The new Equity in Antimicrobial Stewardship Efforts (EASE) is a comprehensive set of priorities designed to overcome inequities and address the challenges with prescribing practices within the minoritized populations.
Watch
FDA Approves Antibiotic for Uncomplicated UTIs
April 24th 2024Pivmecillinam (Pivya) was given the nod from the federal agency, and is indicated for female adults with uncomplicated urinary tract infections (UTIs) caused by susceptible isolates of Escherichia coli, Proteus mirabilis and Staphylococcus saprophyticus.
Read More
European Commission Approves Pfizer’s Antibiotic Combination for Multidrug-Resistant Infections
April 23rd 2024With this approval, aztreonam-avibactam becomes the first β-lactam/β-lactamase inhibitor antibiotic combination approved in the European Union for treating multidrug-resistant infections, including metallo-β-lactamase-producing bacteria.
Read More